Mono Vaccine Market Estimated To Witness a Phenomenal Growth by 2022

Worldwide Market Reports added Latest Research Report titled “Mono Vaccine Market Estimated To Witness a Phenomenal Growth by 2022”.

Mononucleosis (mono) also called as glandular fever is infectious disease caused by Epstein-Barr virus (EBV), which can be transmitted through saliva, exposure to cough or sneeze, and by sharing a glass or food utensils with person suffering from mono. This infection is characterized by various symptoms such as fatigue, sore throat, fever, swollen lymph nodes in neck and armpits, swollen tonsils, headache, and skin rash. Although, there is no specific treatment option is avaible for this disease, consumption of adequate amount of nutrition and fluid can help in improving diseased condition.

Request Sample Copy of the Business Report @ https://www.worldwidemarketreports.com/sample/147128

Increasing prevalence of infectious disease and lack of availability for treatment option are major factors driving growth of the mono vaccine market. According to the National Institute of Environmental Health Sciences, autoimmune diseases affects more than 23.5 million Americans annually. Research studies have reported link between EBV infection and high risk of developing autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus. For instance, in April 2018, researchers at Cincinnati Children’s Hospital Medical Center reported that a protein synthesized by the Epstein-Barr virus binds to areas of the human genome linked to an increased risk of certain diseases such as multiple sclerosis, rheumatoid arthritis, juvenile idiopathic arthritis, inflammatory bowel disease, celiac disease, and Type 1 diabetes. However, high cost of research and development and long period for reaching the end-product to market due to various tests and clinical trial are major factors restraining growth of the mono vaccine market.

Key Developments of Mono Vaccine Market

Several research organizations are working on developing vaccine or treatment for prevention of EBV infections. In April 2018, researchers from Fred Hutchinson Cancer Research Center and the University of Washington discovered human antibody that can block EBV infection. Discovery of new antibody along with its target site is creating new opportunities for development of effective vaccine against EBV virus. Furthermore, in 2017, University of Kansas School of Engineering and School of Pharmacy conducted study to analyze the genetics of human immune responses to develop the basis of an effective vaccine or drug therapy against EBV. Manufacturers are majorly investing in research and development for introducing effective vaccine against EBV infection.

Get discount on this report : https://www.worldwidemarketreports.com/discount/147128

Major players operating in mono vaccine market include CNBG, Serum Institute of India, Biokangtai, Merck, Pfizer, GSK, and Sanofi Pasteur

**If you have any special requirements, please let us know and we will offer you the report as you want.

About WMR :

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

1001 4th Ave,

U.S

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

WEBSITE : https://www.worldwidemarketreports.com/

This release was published on openPR.